950691-52-8 Usage
General Description
6-Chloro-3-fluoronicotinaldehyde is a chemical compound with the molecular formula C6H3ClFNO. It is a derivative of nicotinaldehyde, a heterocyclic aromatic aldehyde compound. This chemical is characterized by the presence of a chlorine and fluorine atom attached to the 6th and 3rd carbon atoms of the nicotinaldehyde ring, respectively. 6-Chloro-3-fluoronicotinaldehyde has been studied for its potential applications in organic synthesis and as a building block for the preparation of various pharmaceutical compounds. Its unique structural features and reactivity make it a valuable intermediate in the synthesis of complex organic molecules. Overall, 6-Chloro-3-fluoronicotinaldehyde is an important chemical with potential uses in various fields including pharmaceuticals, agrochemicals, and materials science.
Check Digit Verification of cas no
The CAS Registry Mumber 950691-52-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,5,0,6,9 and 1 respectively; the second part has 2 digits, 5 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 950691-52:
(8*9)+(7*5)+(6*0)+(5*6)+(4*9)+(3*1)+(2*5)+(1*2)=188
188 % 10 = 8
So 950691-52-8 is a valid CAS Registry Number.
InChI:InChI=1/C6H3ClFNO/c7-6-5(8)1-4(3-10)2-9-6/h1-3H
950691-52-8Relevant articles and documents
GPR139 RECEPTOR MODULATORS
-
Page/Page column 101, (2021/06/26)
Compounds are provided that modulate the GPR139 receptor, compositions containing the same, and to methods of their preparation and use for treatment of a malcondition wherein modulation of the GPR139 receptor is medically indicated or beneficial. Such compounds have the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein R1, R4, R5, R9, R10, Q6, Q7, and Q12 are as defined herein.
ISOXAZOLIDINE DERIVED INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE 1 (RIPK 1)
-
Page/Page column 99; 163; 164, (2017/07/18)
The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.
COMPOUNDS
-
Page/Page column 31, (2012/06/30)
Disclosed are compounds that inhibit Lp-PLA2 activity, processes for their preparation, compositions containing them and their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.
